If you have been reading about AOD-9604 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-08-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
A literary centre for many centuries, Turin began to attract writers only after the establishment of the court of the Dukes of Savoy. One of the most famous writers of the 17th century was Giambattista Marino, which in 1608 moved to the court of Charles Emmanuel I. Marino suffered an assassination attempt by a rival, Gaspare Murtola, and was later imprisoned for a year because of gossip that he had said and written against the duke. Perhaps, because of this, in 1615 Marino left Turin and moved to France. The main literary figures during the Baroque age in Turin were Emanuele Tesauro and Alessandro Tassoni. In the next century Torino hosted the poet Vittorio Alfieri from Asti for a while. The situation was very different in the 19th century, especially since the city became a point of reference for Italian unification and, subsequently, the capital of the Kingdom of Italy. Indeed, in those years Tommaseo, Settembrini and John Meadows resided in the city. A major literary and cultural woman of that time was Olimpia Savio. In the late 19th and early 20th centuries, Turin was home to writers such as Guido Gozzano, Edmondo De Amicis, Emilio Salgari and Dino Segre, the latter known by the pseudonym of Pitigrilli. Turin had a very important role in Italian literature after World War II. A major publishing house, Giulio Einaudi, published works by authors such as Cesare Pavese, Italo Calvino, Vitaliano Brancati, Primo Levi, Natalia Ginzburg, Fernanda Pivano, Beppe Fenoglio, Carlo Fruttero and Franco Lucentini.
ATP–CP system (phosphagen system) – At maximum intensity, this system is used for up to 10–15 seconds. The ATP–CP system neither uses oxygen nor produces lactic acid if oxygen is unavailable and is thus called alactic anaerobic. This is the primary system behind very short, powerful movements like a golf swing, a 100 m sprint or powerlifting. Anaerobic system – This system predominates in supplying energy for intense exercise lasting less than two minutes. It is also known as the glycolytic system. An example of an activity of the intensity and duration that this system works under would be a 400 m sprint. Aerobic system – This is the long-duration energy system. After five minutes of exercise, the O2 system is dominant. In a 1 km run, this system is already providing approximately half the energy; in a marathon run it provides 98% or more. Around mile 20 of a marathon, runners typically "hit the wall," having depleted their glycogen reserves they then attain "second wind" which is entirely aerobic metabolism primarily by free fatty acids.
=== Tunable resistive pulse sensing instruments === The Exoid is the most recent tunable resistive pulse sensing instrument developed by Izon Science and incorporates automated systems to avoid the extensive manual tuning associated with the qNano. Previously, with the qNano, there were many manual components: nanopore stretch had to be adjusted manually using a handle, and pressure was adjusted manually via a variable pressure module (VPM). In contrast, the Exoid automatically adjusts stretch, voltage and pressure, after parameters are selected using the software. The Exoid is capable of measuring the size, concentration, and zeta potential of individual particles sized between approximately 40 nm and 10 μm. The qNano is the original TRPS instrument by Izon Science, and remained the main TRPS instrument from its release in June 2009 until it was replaced by the Exoid in March 2021. Unlike the qNano, the Exoid has built-in semi-automated components for controlling pressure and nanopore stretch, and an enhanced voltage clamp amplifier. The qNano required manual tuning to adjust the stretch of the nanopore and the electrokinetic pressure, while voltage was selected via the software program. Nanopore stretch was adjusted using a handle, while pressure was adjusted by using a variable pressure module to manage a tube and plunger system. There were several updates to the qNano following its release including the addition of a pressure readout module.
The modern method of embalming involves the injection of various chemical solutions into the arterial network of the body to primarily disinfect and slow the decomposition process. William Harvey, the 17th century English physician who was the first to detail the system of blood circulation, made his discoveries by injecting colored solutions into corpses. The Scottish surgeon William Hunter was the first to apply these methods to the art of embalming as part of mortuary practice. He wrote a widely read report on the appropriate methods for arterial and cavity embalming in order to preserve bodies for burial. His brother, John Hunter, applied these methods and advertised his embalming services to the general public from the mid-18th century. One of his more notorious clients was dentist Martin Van Butchell. When his wife Mary died on 14 January 1775, he had her embalmed as an attraction to draw more customers. Hunter injected the body with preservatives and color additives that gave a glow to the corpse's cheeks, replaced her eyes with glass eyes, and dressed her in a fine lace dress. The body was embedded in a layer of plaster of Paris in a glass-topped coffin. Butchell exhibited the body in the window of his home and many Londoners came to see it; however, Butchell drew criticism for the display. A rumor, possibly started by Butchell himself, claimed that his wife's marriage certificate had specified that her husband would only have control over her estate after her death for as long as her body was kept unburied.
Sources: en.wikipedia.org
== Personal life == Studied a Bachelor of Business at RMIT University and currently lives in Sydney with his wife Kirsty. David and Kirsty have a two-year-old daughter, Matilda and will soon have a second child. David completed postgraduate studies at Sydney University and now works for Deloitte as a senior analyst.
==== Host-targeting antivirals ==== Unlike DAAs that target viral proteins, host targeting antivirals (HTAs) inhibit host proteins involved in viral infection and replication. Many viruses utilize common processes to enter host cells and create viral replicates. Because HTAs target processes that are commonly conserved by multiple viral strains, HTAs have the potential to be used as broad spectrum antivirals (BSAs) with activity against multiple viral infections. Processes that are common targets of HTAs include viral entry into the host cell, viral replication, nuclear import and export, and viral release from the host cell. HTAs are attractive to physicians because they have a higher genetic barrier to resistance than DAAs. Host genomes are generally more stable than viral genomes (particularly RNA viruses that are known for their high genetic instability and rapid mutation rate) due to the presence of DNA polymerase proofreading capabilities that corrects point mutations in genetic replication. Taken together, the genetic barrier of HTAs and stability of host cell genomes increase the amount of time it takes for resistance to develop to HTAs. Commonly used FDA-approved HTAs include maraviroc, and interferon. Maraviroc binds to the CCR5 receptor on the surface of host cells. The CCR5 receptor is internalized, and HIV is unable to bind to it, thus inhibiting HIV entry into host macrophages and T-cells.
== Principle of chemical ligation == The "chemical ligation" concept was introduced by Kent in the early 1990s. It consisted of a novel approach to the covalent condensation of unprotected peptide segments by means of "unique, mutually reactive functionalities, one on each reacting peptide segment, designed to react only with each other and not with any of the functional groups found in (native) peptides". Chemical ligation of unprotected peptides is enabled by formation of an unnatural moiety, i.e. non-peptide bond, linking the two peptide segments in the ligation product. It was envisioned as a general method that would greatly simplify the chemical synthesis of protein molecules and enable the application of the entire repertoire of chemistry to the world of the proteins.
Sources: en.wikipedia.org
Non-focal symptoms such as amnesia, confusion, incoordination of limbs, unusual cortical visual symptoms (such as isolated bilateral blindness or bilateral positive visual phenomena), headaches and transient loss of consciousness are usually not associated with TIA, however patient assessment is still needed. Public awareness on the need to seek a medical assessment for these non-focal symptoms is also low, and can result in a delay by patients to seek treatment Symptoms of TIAs can last on the order of minutes to one–two hours, but occasionally may last for a longer period of time. TIA is defined as ischemic events in the brain that last less than 24 hours. Given the variation in duration of symptoms, this definition holds less significance. A pooled study of 808 patients with TIAs from 10 hospitals showed that 60% lasted less than one hour, 71% lasted less than two hours, and 14% lasted greater than six hours. Importantly, patients with symptoms that last more than one hour are more likely to have permanent neurologic damage, making prompt diagnosis and treatment important to maximize recovery.
The use of displacement chromatography is rather limited, and is mostly used for preparative chromatography. The basic principle is based on a molecule with a high affinity for the chromatography matrix (the displacer) which is used to compete effectively for binding sites, and thus displace all molecules with lesser affinities. There are distinct differences between displacement and elution chromatography. In elution mode, substances typically emerge from a column in narrow, Gaussian peaks. Wide separation of peaks, preferably to baseline, is desired in order to achieve maximum purification. The speed at which any component of a mixture travels down the column in elution mode depends on many factors. But for two substances to travel at different speeds, and thereby be resolved, there must be substantial differences in some interaction between the biomolecules and the chromatography matrix. Operating parameters are adjusted to maximize the effect of this difference. In many cases, baseline separation of the peaks can be achieved only with gradient elution and low column loadings. Thus, two drawbacks to elution mode chromatography, especially at the preparative scale, are operational complexity, due to gradient solvent pumping, and low throughput, due to low column loadings. Displacement chromatography has advantages over elution chromatography in that components are resolved into consecutive zones of pure substances rather than "peaks".
==== United Kingdom ==== In the United Kingdom, AAS are classified as class C drugs, which puts them in the same class as benzodiazepines. AAS are in Schedule 4, which is divided in 2 parts; Part 1 contains most of the benzodiazepines and Part 2 contains the AAS. Part 1 drugs are subject to full import and export controls with possession being an offence without an appropriate prescription. There is no restriction on the possession when it is part of a medicinal product. Part 2 drugs require a Home Office licence for importation and export unless the substance is in the form of a medicinal product and is for self-administration by a person.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.